Licencing Deal Expands Noxopharm Drug Opportunities
Filed with ASX · · 5 pages · English
In the deck
Earlier from Noxopharm
- Retraction of Grant Announcement
- Noxopharm Awarded A$8.8M Aust Govt Grant for Sarcoma Trial
- Noxopharm Announces DARRT-2 Clinical Trial in U.S.
- Veyonda and Opdivo IONIC Study First Patient Dosed
- Patent Granted for Veyonda and Low Dose Chemotherapy
Later from Noxopharm
- Noxopharm In-Licenses Novel RNA Technology From Hudson Institute of Medical Research
- Noxopharm DARRT-2 Cancer Trial Update
- Noxopharm Announces Leadership Transition
- Noxopharm Receives A$5.865M R & D Tax Rebate
- December 2021 Quarterly Activities Report and Appendix 4C
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm